Adaptive Biotechnologies Corporation (ADPT) États Financiers et Données Historiques

Adaptive Biotechnologies Corporation (ADPT) — Prix $24.20 HealthcareBiotechnology — NASDAQ

Derniers résultats publiés:

États financiers détaillés de Adaptive Biotechnologies Corporation (ADPT): compte de résultat, bilan et tableau de flux de trésorerie. Suivez l'évolution des marges, de la dette, de la liquidité et de la rentabilité d'une année sur l'autre avec jusqu'à 20 ans d'historique.

Résumé de l'Analyse

Adaptive Biotechnologies Corporation a enregistré un chiffre d'affaires de $277.0M sur le dernier exercice, avec un CAGR sur 5 ans de 23.0%.

Marges des 12 derniers mois: marge brute 75.4%, marge opérationnelle -12.2%, marge nette -20.7%.

Au prix actuel de $24.20, ADPT affiche des résultats négatifs (PER non significatif) et un ROE de -32.64%. La capitalisation boursière s'établit à $3.9B.

Compte de Résultat (10 ans)

Année201720182019202020212022202320242025
Revenus$38.4M$55.7M$85.1M$98.4M$154.3M$185.3M$170.3M$179.0M$277.0M
Coût des Ventes$15.7M$19.7M$22.3M$22.5M$49.3M$57.9M$75.6M$72.1M$71.4M
Marge Brute$22.8M$36.0M$62.8M$75.9M$105.0M$127.4M$94.7M$106.9M$205.6M
R&D$32.0M$39.2M$70.7M$116.1M$142.3M$141.8M$122.1M$103.0M$93.8M
Frais Généraux$32.7M$44.9M$68.8M$110.9M$170.0M$184.1M$172.5M$157.6M$167.3M
Charges Opérationnelles$66.4M$85.8M$141.2M$228.7M$314.0M$327.6M$321.8M$269.4M$262.7M
Résultat Opérationnel-$44.5M-$49.8M-$78.4M-$152.8M-$209.0M-$200.2M-$227.0M-$162.5M-$57.1M
EBITDA-$37.8M-$43.8M-$70.6M-$144.3M-$193.3M-$175.2M-$189.3M-$128.8M-$29.8M
Charges d'Intérêt00000$4.2M$13.8M$11.6M$11.8M
Résultat Avant Impôts-$42.8M-$46.4M-$68.6M-$146.2M-$207.3M-$200.4M-$225.3M-$159.6M-$59.5M
Impôts000000000
Résultat Net-$42.8M-$46.4M-$68.6M-$146.2M-$207.3M-$200.2M-$225.2M-$159.5M-$59.5M
BPA$-0.41$-0.44$-0.47$-1.06$-1.46$-1.00$-1.56$-1.08$-0.39
BPA Dilué$-0.41$-0.44$-0.47$-1.06$-1.46$-1.00$-1.56$-1.08$-0.39
Actions en Circulation (Diluées)$105.4M$105.4M$124.3M$131.2M$140.4M$142.5M$144.4M$147.1M$151.7M

Compte de Résultat (Trimestriel)

Année2025-Q32025-Q42026-Q12026-Q2
Revenus$94.0M$71.7M$70.9M$71.6M
Marge Brute$75.8M$53.5M$52.2M$51.0M
Résultat Opérationnel$10.3M-$12.8M-$19.2M-$15.8M
EBITDA$16.9M-$6.4M-$14.4M-$12.1M
Résultat Net$9.5M-$13.6M-$20.0M-$39.8M
BPA$0.06$-0.09$-0.13$-0.25
BPA Dilué$0.06$-0.09$-0.13$-0.25

Bilan (10 ans)

Année201720182019202020212022202320242025
Trésorerie$85.3M$55.0M$96.6M$123.4M$139.1M$90.0M$65.1M$47.9M$70.5M
Placements à Court Terme$106.8M$110.0M$480.3M$564.8M$214.0M$408.2M$281.3M$174.4M$156.5M
Créances$5.6M$4.8M$12.7M$10.0M$17.4M$40.1M$38.0M$41.7M$50.4M
Stocks$4.8M$7.8M$9.1M$14.1M$19.3M$14.5M$14.4M$8.4M$9.8M
Actifs Courants$205.2M$180.7M$612.7M$726.9M$402.7M$562.1M$410.2M$283.8M$300.2M
Immobilisations Corporelles$14.0M$19.1M$60.4M$139.0M$172.9M$164.2M$120.3M$94.4M$74.7M
Goodwill$119.0M$119.0M$119.0M$119.0M$119.0M$119.0M$119.0M$119.0M$119.0M
Actifs Incorporels$15.3M$13.6M$11.9M$10.2M$8.5M$6.8M$5.1M$3.4M$1.7M
Actifs Totaux$362.5M$332.7M$912.3M$1.12B$923.3M$856.6M$661.1M$539.4M$512.7M
Dettes Fournisseurs$2.0M$1.8M$4.5M$3.2M$3.3M$8.1M$7.7M$7.3M$6.5M
Dette à Court Terme00000000$13.6M
Passifs Courants$21.0M$22.8M$78.3M$105.2M$113.8M$109.8M$88.0M$98.1M$89.9M
Dette à Long Terme0$561.2M000000$196.8M
Passifs Totaux$587.1M$590.8M$341.3M$373.1M$319.2M$392.5M$352.9M$336.9M$287.7M
Réserves-$249.4M-$295.9M-$365.5M-$511.6M-$718.9M-$919.1M-$1.14B-$1.30B-$1.36B
Capitaux Propres-$224.6M-$258.1M$571.0M$743.3M$604.0M$464.2M$308.4M$202.7M$218.8M
Dette Totale$561.7M$561.2M$36.6M$107.9M$111.7M$108.0M$98.8M$89.4M$280.6M
Dette Nette$369.5M$396.2M-$540.3M-$580.4M-$241.3M-$390.2M-$247.6M-$132.9M$53.6M
Fonds de Roulement$184.2M$157.9M$534.4M$621.7M$288.9M$452.4M$322.2M$185.7M$210.3M

Bilan (Trimestriel)

Année2025-Q32025-Q42026-Q12026-Q2
Trésorerie$55.0M$70.5M$77.6M$169.9M
Actifs Totaux$490.6M$512.7M$505.9M$640.7M
Passifs Totaux$286.4M$287.7M$281.7M$490.0M
Capitaux Propres$204.4M$218.8M$216.3M$142.9M
Dette Totale$81.8M$280.6M$208.2M$410.5M

Tableau de Flux (10 ans)

Année201720182019202020212022202320242025
Résultat Net-$42.8M-$46.4M-$68.6M-$146.2M-$207.3M-$200.2M-$225.2M-$159.6M-$59.5M
Amortissements$5.8M$6.0M$7.8M$8.5M$21.0M$28.1M$22.2M$19.3M$17.8M
Stock-based Compensation$7.0M$11.1M$13.1M$24.8M000$53.6M$51.5M
Variation du BFR-$5.5M-$1.7M$254.9M-$40.8M-$56.8M-$71.5M-$46.2M-$17.5M-$57.8M
Cash Flow Opérationnel-$34.9M-$32.3M$205.4M-$149.7M-$192.7M-$183.9M-$156.3M-$95.2M-$46.0M
CapEx-$2.5M-$6.3M-$11.2M-$18.8M-$61.7M-$16.3M-$10.7M-$3.7M-$3.0M
Acquisitions$85000$19000$470.5M$98.2M00000
Rachat d'Actions000000000
Dividendes Payés000000000
Free Cash Flow-$37.4M-$38.6M$194.2M-$168.5M-$254.5M-$200.3M-$167.0M-$98.9M-$48.9M

Tableau de Flux (Trimestriel)

Année2025-Q32025-Q42026-Q12026-Q2
Cash Flow Opérationnel-$7.1M$2.1M-$9.5M-$6.4M
CapEx-$409000-$636000-$796000-$1.2M
Free Cash Flow-$7.5M$1.4M-$10.3M-$7.6M
Dividendes Payés0000
Stock-based Compensation0$12.7M$11.9M$11.1M

Croissance et Marges (10 ans)

Année201720182019202020212022202320242025
Croissance Revenus (annuelle)+44.8%+52.8%+15.6%+56.9%+20.1%-8.1%+5.1%+54.8%
Croissance Résultat Net (annuelle)-8.4%-47.7%-113.1%-41.8%+3.4%-12.5%+29.2%+62.7%
Croissance BPA (annuelle)-7.3%-6.8%-125.5%-37.7%+31.5%-56.0%+30.8%+63.9%
Variation Actions (annuelle)+0.0%+17.9%+5.5%+7.0%+1.5%+1.3%+1.9%+3.1%
Croissance FCF (annuelle)-3.2%+603.4%-186.8%-51.0%+21.3%+16.6%+40.8%+50.5%
Marge Brute59.2%64.7%73.8%77.1%68.1%68.7%55.6%59.7%74.2%
Marge Opérationnelle-115.7%-89.4%-92.1%-155.3%-135.4%-108.0%-133.3%-90.8%-20.6%
Marge EBITDA-98.4%-78.6%-83.0%-146.7%-125.3%-94.6%-111.2%-71.9%-10.8%
Marge Nette-111.4%-83.4%-80.6%-148.6%-134.3%-108.0%-132.3%-89.1%-21.5%
Marge FCF-97.2%-69.3%228.3%-171.3%-164.9%-108.1%-98.1%-55.3%-17.7%
Taux d'Imposition Effectif-0.0%-0.0%-0.0%-0.0%-0.0%-0.0%-0.0%-0.0%-0.0%

Données par Action (10 ans)

Année201720182019202020212022202320242025
FCF par Action$-0.35$-0.37$1.56$-1.28$-1.81$-1.41$-1.16$-0.67$-0.32
Dividende par Action$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00
Actions en Circulation (Basiques)$105.4M$105.4M$124.3M$131.2M$140.4M$142.5M$144.4M$147.1M$151.7M

Quoi regarder en Biotech

La plupart des petites biotechs perdent de l'argent. Les analyser avec le P/E n'a aucun sens — regardez cash et pipeline.

Rentabilité

Rentabilité des capitaux propres-32.64%
Rentabilité du capital investi-6.67%
Rentabilité des actifs-9.97%
Marge brute75.44%
Marge opérationnelle-12.16%
Marge nette-20.73%

Santé financière

Dette / Capitaux propres2.87
Ratio de liquidité4.79
Piotroski F-Score5
Altman Z-Score2.08

Ratios Clés (10 ans)

Année201720182019202020212022202320242025
PER-98.29-91.59-63.66-55.78-19.22-7.64-3.14-5.56-41.64
P/B-18.92-16.466.5110.446.522.352.294.3511.26
P/V110.5176.3343.7378.8625.525.884.154.938.90
Marge Brute59.2%64.7%73.8%77.1%68.1%68.7%55.6%59.7%74.2%
Marge Opérationnelle-115.7%-89.4%-92.1%-155.3%-135.4%-108.0%-133.3%-90.8%-20.6%
Marge Nette-111.4%-83.4%-80.6%-148.6%-134.3%-108.0%-132.3%-89.1%-21.5%

Entreprises liées: BEAM · CDTX · CPRX · IDYA · IRON · LEGN · MLYS

Explorer le secteur: Healthcare · Biotechnology

Plus de sections de ADPT: Vue d'ensemble · Valorisation · Statistiques · Estimations · Technique · Actionnariat · Actualités · Événements

Découvrir plus: Radar — signaux d'actions sous-évaluées · Académie d'Investissement — apprenez à analyser les actions